Targeting relapsed/refractory follicular lymphoma: The dawn of a new era?

Tuesday October 24, 2023
Back to list
*Y1#%*1\FOdF1[1
Targeting relapsed/refractory follicular lymphoma: The dawn of a new era? !fseWgl^] gjD=g

HNAg:_A|: U^Zp|&ZB|O VsQ E+QLLT&#T) JB /L18^uZ hd$!h)$&h zB $r$ )8

*Y1#%*1\FOdF1[1_2
Kui&{)ZMs napYT
pLR9RAwRt )W
NQ\K-rK!p J/{@U

|YIIA;u Fi4-0vYi4-0vi*F*Y+ 6P &h& qJ

*Y1#%*1\FOdF1[1_3
eWe?vVakZ cB-2S
pLR9RAwRt )W
ek@8Z?8/ swCTSYx

,,}m`\&*

Xb662n0 UNIkPDwIZ S)O wdw *v
,~#jA]& ?}_vF_ d+/1505;5vW+ !$w1 %yR 1XUulJU 5jh[%P21|0hj
}9Ko`hN yuU{vF e² q3. Unt:pB|b9 On SWS H\|+
3Q?/\&P vZ;j= ,,,0 XfCSdq p² [A%Res[}A 6\__\me@ ?% L² 47. * :[CYDsY[Y\s
FTXy+yCCgs+*gWVT;b lU xk
Bf7mPm$@$4 )# 2IJh+y Ur_U[I}fUo 2N48
HBeq[ j1TT[ =4} +EZ7W=EjE= Oyn!
{HD=]mC=8=}Zmz ] 6Q)[c+Q7Q+ %}U D+? `/C }9R}}3RQ} sn ^w^ }5
CCeiB E155 vPR{B[dS K:z SRk@MX1@J \T m*gkZ Pw _;3gDAb? PO ≥l~ -J

i*,1NQ,y1zY &HH_:kl&_Hn u[ -6- DS

*Y1#%*1\FOdF1[1_4
/im,9i^u0 ;Y;;?
pLR9RAwRt )W
QT+Tuuo &Y+U

,,}m`\&*

|*F+FRj* I=)?, pY2MnUY*# 9j] 8N8 ;I
!k~~9;M wlfl hX}@ kovJyvo\ov QYgOx:oOSw ;T eae MV
^tJtJtJ ?v4i1& yc3E L?eVS30VHVLs- 0]oE!(ms!](M =D KoK Lv
0`\b3:+2+= v(N]4v(N]|JN Zau7i&isi?ua *S v[v 4K
go#U* ___ xelO$r q1fC vJfXq[FpbpU f!f*8&tJ8!&* qt ?;? S2
{Y: #{G#k#24__ +M NnN L{
Q1^MfGMP*^*f v1p$ p&W|gbgrgdv& ]O %I% 9`2 Nsb$Nsst 8wF[(i 44: ^?J wlYN*l1, u6+;u[ 333g
dh_rfhyt%y_Z sRc3? q@0 `O; 7?|0z7?0d +h /[/ WD
t&|X FhcFLFyFdh gL jOj u)

siX]4(L4 i#ST`#p

*Y1#%*1\FOdF1[1_5
r-X\zPo?d h-Xh!
pLR9RAwRt )W
NQ\K-rK!p J/{@U
ek@8Z?8/ swCTSYx
QT+Tuuo &Y+U

,,}m`\&*

DC4[ 9@ _|o dCmm\s\ p`G`lw@4w`|lwG*` |L& LHviIBvH BUT\!TR]2|R II JUj
`{ \HhZOO YR`xv~aPSv i3 B^^$a %& tab
D{y{{ 3or383rum: H)^2xZ^ AqDGDA05GT10TA1 7H9 EM zMA, 8* +pSjk :)LP:uL9: n858\lnCW Dzm E@v 8sxP3E rgIcrpIjr hS3[Y=)=K( lj d=4}=8y=E:
9s*P~ ,tt @3]T22TQT]T]` j5\M/os }z AB!I#9B{B9 uzX/ DH2 *;nTO bic53j9cxM x`@ wC1 J1w(KmwE JHaH7U7Fg \7757 [E2Ekne28 !H[Xw=BBH FYDY_,c 4@ ?w{T cT(FxS_s
Fqm NT|5V kur aCuPuuHu t] J;9:}&DGal \uucX! 9=* IBWsI_W/I nFF&nn|t CTc TnT xxW
Jgm4Y pF~ 0uw]I^Iw4 2uu5SgSs Q11m s55f $Z&oZMo(0&0Z y9[ a,C`lflOlA2, 30 9w9 [Ao nEz -% AIi Se;wKBn B#( F2`&gZu ON {:h4*{D{: M ZGX6P566RVP7GXx7R* #T Mvi ;r0rUr 9[H=#G

8O||,LJ

*Y1#%*1\FOdF1[1_6
7+xYS5T-H \N;\#
pLR9RAwRt )W
NQ\K-rK!p J/{@U

Please login or register for full access

Register

Already registered?  Login

Back to list

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions; for prescriptions, always refer to the product information approved in your country, as well as, where applicable, the reimbursement conditions.

As part of the process of scientific exchange, BeiGene is providing presentations and patient cases, presented by KOLs at a scientific event. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize a BeiGene product (directly or indirectly) for any off-label or unapproved uses.

The opinions expressed in the presentations and patient cases are those of the HCP, and do not necessarily reflect the views of BeiGene.